Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas.

Hassan Nelson, Lauren; Fuentes-Bayne, Harry; Yin, Jun; Asmus, Erik; Ryder, Mabel; Morris, John C; Hilger, Crystal R; Bible, Keith C; Chintakuntlawar, Ashish V; Rao, Sarika N

Hassan Nelson, Lauren; Fuentes-Bayne, Harry; Yin, Jun; Asmus, Erik; Ryder, Mabel; Morris, John C; Hilger, Crystal R; Bible, Keith C; Chintakuntlawar, Ashish V; Rao, Sarika N.

Afiliação

Hassan Nelson L; Division of Endocrinology, Mayo Clinic, Jacksonville, FL 32224, USA.
Fuentes-Bayne H; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Yin J; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Asmus E; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
Ryder M; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Morris JC; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Hilger CR; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Bible KC; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Chintakuntlawar AV; Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Rao SN; Division of Endocrinology, Mayo Clinic, Jacksonville, FL 32224, USA.

J Endocr Soc ; 6(5): bvac044, 2022 May 01.

Article em En | MEDLINE | ID: mdl-35402763

Palavras-chave

cancer; multikinase inhibitor; paraganglioma; pheochromocytoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: J Endocr Soc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google